

THIS ANNOUNCEMENT IS NOT FOR RELEASE, PUBLICATION OR DISTRIBUTION, DIRECTLY OR INDIRECTLY, IN OR INTO THE UNITED STATES, AUSTRALIA, CANADA, JAPAN OR ANY JURISDICTION WHERE TO DO SO WOULD BE UNLAWFUL. OTHER RESTRICTIONS ARE APPLICABLE. PLEASE SEE THE IMPORTANT LEGAL NOTICE AT THE END OF THIS ANNOUNCEMENT.



## Regulated information

# Information on the total number of voting rights and shares

**Brussels, Belgium, 3 October 2019, 5.45 pm (CEST) – ASIT biotech (ASIT - BE0974289218)**, a clinical stage biopharmaceutical company focused on the research, development and future commercialization of breakthrough immunotherapy products for the treatment of allergies, discloses the information required under article 15 of the Belgian law of 2 May 2007 regarding the disclosure of important shareholdings in listed companies.

### Denominator – modified on 3 October 2019 following a capital increase:

- New shares issued following the capital increase: 496,920
- Total number of shares with voting rights: 21,200,369
- Total number of voting rights (=denominator): 21,200,369

Total number of shares with voting rights upon capital increase: 21,200,369

\*\*\*

### About ASIT biotech

ASIT biotech is a Belgian clinical stage biopharmaceutical company focused on the development and future commercialization of a range of breakthrough immunotherapy products for the treatment of allergies. Thanks to its innovative ASIT+™ technology platform, ASIT biotech is currently the only developer of allergy immunotherapy (AIT) product candidates consisting of a unique mixture of highly purified natural allergen fragments in an optimal size selection. This innovation results in a short treatment, expected to improve patient compliance and real-life effectiveness. ASIT biotech's product pipeline contains three novel ASIT+™ product candidates targeting respiratory allergies with the highest prevalence (i.e. grass pollen: gp-ASIT+™ - in ongoing phase III - and house dust mite: hdm-ASIT+™), and food allergies (peanut allergy: pnt-ASIT+™) that could significantly expand the current immunotherapy market. The Company believes that its innovative ASIT+™ platform is flexible and would be applicable across a range of allergies.

Further information can be found at [www.asitbiotech.com](http://www.asitbiotech.com)

Follow us on [LinkedIn](#)

### Contacts

#### Company

Michel Baijot, CEO  
ASIT biotech  
Tel.: +32 2 264 03 90  
[investors@asitbiotech.com](mailto:investors@asitbiotech.com)

#### Investor Relations

LifeSci Advisors LLC  
Hans Herklots  
Tel.: +41 79 598 7149  
[hherklots@lifesciadvisors.com](mailto:hherklots@lifesciadvisors.com)



#### Media Relations

Sophie Baumont  
Tel.: +33 627 74 74 49  
[sophie@lifesciadvisors.com](mailto:sophie@lifesciadvisors.com)

**Legal notice**

This announcement is for information purposes only and does not constitute an offer to sell or a solicitation of an offer to buy or subscribe for the Company's shares in any jurisdiction. This announcement does not constitute a prospectus. Any purchase of, subscription for or application for, Shares to be issued in connection with the intended offering should only be made on the basis of information contained in the prospectus and any supplements thereto, as the case may be.

**Forward-looking statements**

This release may contain forward-looking statements. Such forward-looking statements are not guaranteeing future results. These forward-looking statements speak only as of the date of publication of this document. The Company expressly disclaims any obligation to update any forward-looking statements in this document, unless specifically required by law or regulation.